Response to chemotherapy can be predicted using patient-derived organoids


There is a great need for a test that can predict which patients will respond to  chemotherapy and which will not. In a clinical study with 61 metastatic colorectal cancer patients, researchers from the Netherlands Cancer Institute, led by Emile Voest, now showed that a specific second-line chemotherapy treatment can first be tested on organoids: these are 'mini tumours' that have  been laboratory grown from a small piece of the same patients' tumour tissue.  

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.